Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Saeid Babaei Insider Profile
4 Followers
Saeid Babaei, Director at BriaCell Therapeutics, holds 495.23K shares in BriaCell Therapeutics (Ticker: TSE:BCT). Most recently, Saeid Babaei Bought C$150,000 shares of BriaCell Therapeutics on Mar 21, 2018 for an estimated value of 21.00K.
Saeid Babaei has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
Director
Roles that Saeid Babaei holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Mar 21, 2018 - Mar 21, 2019
Return:-7.90%
The most profitable trade made by Saeid Babaei
Saeid Babaei's Trading History
List of latest transactions for each holding click on a transaction to see Saeid Babaei's performance on stock
You May Also Like
Saeid Babaei insider profile FAQ
What is the percentage of profitable transactions made by Saeid Babaei?
The percentage of profitable transactions made by Saeid Babaei is ―.
What is the average return per transaction made by Saeid Babaei?
The average return per transaction made by Saeid Babaei is ―.
What stocks does Saeid Babaei hold?
Saeid Babaei holds: TSE:BCT stocks.
What was Saeid Babaei’s latest transaction?
Saeid Babaei latest transaction was an Informative Buy of C$21.00K.
What was Saeid Babaei's most profitable transaction?
Saeid Babaei’s most profitable transaction was an Informative Buy of TSE:BCT stock on March 21, 2018. The return on the trade was -7.90%.
What is Saeid Babaei's role in BriaCell Therapeutics?
Saeid Babaei's role in BriaCell Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.